Treatment and prevention of urolithiasis (the presence of primary and recurrent stones of various sizes and localization in the kidneys and urinary tract); complications caused by the passage of stone fragments after shock-wave lithotripsy; in renal colic; prevention of the formation of urinary concretions after their surgical removal and/or self-release; as part of the complex maintenance therapy of chronic pyelonephritis, chronic inflammatory diseases of the lower urinary tract (cystitis, urethritis) and in chronic prostatitis.
Fitolit №30 Storage
active ingredients: 1 capsule contains knotweed ordinary dry extract (7.69: 1) (extractant – purified water) 75 mg, St. John’s wort dry extract (9.26: 1) (extractant – ethanol 50%) 45 mg, horsetail field dry extract (9.17: 1) (extractant – ethanol 50%) 37.5 mg, avisanu (12.5: 1) (extractant – ethanol 70%) 37.5 mg;
excipients: microcrystalline cellulose, colloidal anhydrous silica, calcium stearate; the capsule shell contains indigo carmine (E 132), quinoline yellow (E 104), titanium dioxide (E 171), gelatin.
Fitolit №30 Dosage form
Main physical and chemical properties: hard gelatin capsules of green color. Capsule content – a mixture of granules and powder from light brown to dark brown with a greenish tinge. The presence of agglomerates of powder particles is allowed. It is allowed to apply the trademark of the enterprise – ST on the capsule.
Fitolit №30 Pharmacotherapeutic group
Means that promote the dissolution of urinary stones. Various drugs, including combinations. ATX code G04B C.
Pharmacodynamics. The drug has antispasmodic, diuretic, analgesic and anti-inflammatory effects, has antimicrobial and antiseptic properties, regulates mineral metabolism. Reduces the frequency and intensity of renal colic, normalizes the physicochemical parameters of urine, helps to restore optimal urodynamics and homeostasis of urine, reduces leukocyturia. Promotes leaching of sand and small concretions, prevents increase in concretions or emergence of new ones. The drug has a positive effect on the state of spermatogenesis in experimental prostatitis (increases the concentration of sperm, the duration of sperm motility and the percentage of motile forms, reduces the number of pathologically altered sperm, changes in the positive direction of acid and osmotic resistance).
Pharmacokinetics. Not studied.
Treatment and prevention of urolithiasis (presence in the kidneys and urinary tract of primary and recurrent stones of different size and location); complications caused by the passage of stone fragments after shock wave lithotripsy; with renal colic; prevention of the formation of urinary stones after their surgical removal and / or self-exit; in complex maintenance therapy of chronic pyelonephritis, chronic inflammatory diseases of the lower urinary tract (cystitis, urethritis) and chronic prostatitis.
Hypersensitivity to any components of the drug, thrombophlebitis, changes in the rheological properties of blood, acute inflammatory diseases of the kidneys and bladder, the presence in the urinary tract of stones larger than 6 mm, nephritis, nephrosis, nephrosonephritis, glomerulonephritis; arterial hypertension.
Interaction with other medicinal products and other forms of interaction
It is not recommended for use in patients taking anticoagulants, antibiotics, sulfonamides, contraceptives, antihypertensive calcium channel blockers, female sex hormones, hypocholesterolemic drugs (statins), cardiac glycosides.
If you need to take any other medicines at the same time, you should consult your doctor.